Dr Bali Muralidhar is Managing Partner at Abingworth LLP, a leading transatlantic life sciences investment firm, which has invested in over 175 life science companies since 1973, leading to 46 M&As and 70+ IPOs. Bali has 15 years professional experience in healthcare across a range of functions including venture investing, R&D, clinical practice and teaching. He represents Abingworth on the boards of Anjarium, Exicure Inc., NuCana, Reneo, Spruce Biosciences and Wugen. He led the Abingworth's investment in Glycomine and is an observer on the board. Bali is an executive officer on the joint steering committee of CymaBay and since 2021 Bali has been a member of the BVCA Venture Capital Committee.

Prior to joining Abingworth, Bali was a senior partner at MVM Partners LLP in London. Before MVM, Bali was a member of Bain Capital's healthcare deal team. Bali obtained a degree in clinical medicine from the University of Oxford and practised general surgery at the John Radcliffe and Addenbrooke's Hospitals in Oxford and Cambridge, respectively. He has a PhD in translational cancer research from the MRC Cancer Cell Unit, University of Cambridge, and has published over a dozen peer reviewed papers.